Jumar Bioincubator, Australia’s newest biotech incubator, is seeking expressions of interest from early-stage biotech as part of a Melbourne-based program.
The $30 million incubator will combine early-stage and expanding biotechnology ventures with state-of-the-art facilities, infrastructure and support to turn ideas into cures and commercialize medical research.
Jumar is a climbing technique in which climbers receive support to climb difficult mountains efficiently and quickly. Founding partner CSL, a leader in biotechnology, Wahiand University of Melbourne and B.break through victoria.
Breakthrough Victoria CEO Grant Dooley said the incubator will help build a pipeline of investment opportunities for local innovation and create jobs and investment.
“We are investing in the next generation of founders by providing them with the infrastructure, expertise and support they need through the Jumar Bioincubator,” he said.
It is designed to support research translation for biotech start-ups in fields such as pharma, diagnostics, medical devices, digital health, bioinformatics, and health-oriented AI. This incubator facilitates the commercialization of research and the transformation of innovation by providing biomedical scientists and researchers with access to the knowledge and skills necessary for successful biomedical and biotechnology companies.
a report By Sydney-based Deep Tech Incubator Semi innovationThe company that runs Jumar found that incubator-backed startups had a much higher five-year survival rate (85%) and an accelerated growth trajectory (40%) compared to independent companies. discovered.
Jumar is co-located with a leading biopharmaceutical company in the Melbourne Biomedical District with strengths in clinical research in infectious diseases and immunology, neuroscience (including mental health), cancer, children’s health and healthy aging will be placed.
Located north of the capital’s central business district, it is home to over 40 hospitals, research, education and biotechnology organizations.
Jumar will be located across two floors of CSL’s new global headquarters and research and development center in Melbourne’s biomedical precinct, which will open in September, and will be led by a newly appointed general manager. Camille Shanahan.
Camille has over 15 years of clinical, scientific and commercial experience in the biopharmaceutical field, with a particular focus on translating medical research into clinical applications.
Cicada Innovation CEO Sally Ann Williams said Jumal could boost the growth of commercial biotech outcomes in Australia under the Shanahan government nationally.
“Camille’s passion for the growth of Australia’s biotech industry is evident throughout her career,” she said.
“Her experience and network will help build a thriving community that will lead to a thriving biotech ecosystem not only within Jumal but across the country.”
Dr. Andrew Nash, Chief Scientific Officer of CSL, said moving from a biotech start-up to commercial success requires not only access to capital, but also a shift in capabilities, processes and mindsets. rice field.
“Based at CSL’s global headquarters and R&D centre, residents of the Jumar Bioincubator will receive hands-on support and work in close proximity to CSL’s large and focused R&D team.” she said.
“In keeping with our promise to patients, we look forward to supporting the resident biotech start-ups in translating promising medical research into new treatments and treatments.”
Biotech start-ups can send expressions of interest to the following address: Jumalbio.com